



Vivimed

Date: 18th May 2017

To

BSE Limited
P.J.Towers, Dalal Street,
Mumbai – 400001
BSE - Code : 532660

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
NSE- Symbol: VIVIMEDLAB

Dear Sir/Madam

Sub: Outcome of the Meeting of the Board of Directors of the Company – reg.

Ref: Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors of the Company at its meeting held on May 18, 2017 inter alia, have approved / resolved/ taken note of the following:

1. Incorporation of Vivimed Life Sciences Private Limited (wholly owned subsidiary) in India
2. Incorporation of Vivimed Global Generics Pte Ltd (wholly owned subsidiary) in Singapore
3. divesting of certain intellectual property rights in and certain pharmaceutical products including the United States Food and Drug Administration ("US FDA") approved Abbreviated New Drug Applications ("ANDAs") pertaining to the pharmaceutical manufacturing business of the Company conducted at pharmaceutical formulations plant facility situated on the land at SIDCO Industrial Estate, Alathur Village, Kancheepuram Tamil Nadu ("IP Assets") to its wholly owned subsidiary viz., Vivimed Global Generics Pte Ltd and entering into investment agreement whereby Strides Pharma Global Pte Limited will acquire 50% of the issued and paid up equity capital of Vivimed Global Generics Pte Ltd and establishment of a joint venture between Vivimed Labs Limited and Strides Pharma Global Pte Limited in Vivimed Global Generics Pte Ltd primarily to be engaged in the business of research, development, marketing, distributing and commercialisation of pharmaceuticals products and formulations in regulated markets

Vivimed Labs Ltd. (Corporate Office)

CIN: LD2411KA1988PLC009465

Veernag Towers, Habsiguda, Hyderabad, Telangana - 500 007, India.

T +91 (0) 40-2717 6005/6 F +91 (0) 40-2715 0599

contact@vivimedlabs.com | www.vivimedlabs.com





Vivimed

4. Sell / transfer / hive off and/or dispose of or otherwise transfer to its newly incorporated wholly owned subsidiary Company Viz., Vivimed Life Sciences Private Limited, the Company's certain identified assets /undertakings of the Company pertaining to the pharmaceutical manufacturing business of the Company conducted at pharmaceutical formulations plant facility situated on the land at SIDCO Industrial Estate, Alathur Village, Kancheepuram Tamil Nadu ("Target Business") and entering into investment agreement whereby Strides Shasun Limited will acquire 50% of the issued and paid up equity capital of Vivimed Life Sciences Private Limited and establishment of a joint venture between Vivimed Labs Limited and Strides Shasun Limited in Vivimed Life Sciences Private Limited to primarily manufacture pharmaceutical formulations for the United States of America market.

These transactions are subject to customary closing conditions and expected to be closed by 31st May 2017.

Please find enclosed disclosure under Regulation 30 of SEBI (LODR) on the proposed Joint Ventures.

You are requested to take note of the above.

Yours faithfully
For Vivimed Labs Limited


Santosh Varalwar
Managing Director



Vivimed Labs Ltd. (Corporate Office)

CIN: L02411KA1988PLC009465

Veernag Towers, Habsiguda, Hyderabad, Telangana - 500 007, India.

T +91 (0) 40-2717 6005/6 F +91 (0) 40-2715 0599

contact@vivimedlabs.com | www.vivimedlabs.com

Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No	Particulars		
1.	Name of the Target entity, details in brief such as size, turnover etc.	Vivimed Global Generics Pte Ltd., Singapore Size, Turnover: Not applicable	
2.	Whether the acquisition of the Target entity falls within the related party Transaction and whether the promoter/ promoter group/group companies have any interest in the entity being acquired	Yes	
3.	Industry to which Target entity being acquired belongs	Pharmaceuticals	
4.	Objects and effects of acquisition	Provides access to a strong product pipeline The purpose of investment is to form a Joint Venture with Strides Pharma Global Pte Limited. The JV Company will own certain approved ANDAs and product pipeline from Vivimed Labs Limited	
5.	Brief details of any governmental or regulatory approvals required for the acquisition	None	
6.	Indicative time period for completion	Expected to close by May 31, 2017	
7.	Nature of consideration	Cash	
8.	Percentage of shareholding/ control acquired and/ or number of shares acquired	50%	
9.	Cost of acquisition or the price at which the shares are acquired	INR 9 Crores (Nine Crores Rupees Only)	
10.			
a.	Products/line of business acquired	Pharmaceutical formulations	
b.	Date of incorporation	17.04.2017	
c.	History of last 3 years turnover	FY 2015-16	NA
		FY 2014-15	NA
		FY 2013-14	NA
d.	Country in which the acquired entity has presence	Singapore	
e.	Any other significant information	No	

For VIVIMED LABS LTD.


Managing Director

Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No	Particulars		
1.	Name of the Target entity, details in brief such as size, turnover etc.	Vivimed Life Sciences Private Limited, India Size, Turnover: Not applicable	
2.	Whether the acquisition of the Target entity falls within the related party Transaction and whether the promoter/ promoter group/group companies have any interest in the entity being acquired	Yes	
3.	Industry to which Target entity being acquired belongs	Pharmaceuticals	
4.	Objects and effects of acquisition	Provides additional capacity and de-risking manufacturing infrastructure. The purpose of investment is to form a Joint Venture with Strides Shasun Limited. The JV Company will own US FDA approved formulation facility in Alathur, Chennai from Vivimed Labs.	
5.	Brief details of any governmental or regulatory approvals required for the acquisition	None	
6.	Indicative time period for completion	Expected to close by May 31, 2017	
7.	Nature of consideration	Transfer of formulation facility in Alathur, Chennai	
8.	Percentage of shareholding/ control acquired and/ or number of shares acquired	50%	
9.	Cost of acquisition or the price at which the shares are acquired	INR 14.14 Crores (approximately Fourteen Crores fourteen Lakhs rupees only)	
10.			
a.	Products/line of business acquired	Pharmaceutical formulations	
b.	Date of incorporation	20.02.2017	
c.	History of last 3 years turnover	FY 2015-16	NA
		FY 2014-15	NA
		FY 2013-14	NA
d.	Country in which the acquired entity has presence	India	
e.	Any other significant information	None	

For VIVIMED LABS LTD.


Managing Director